Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Featured Content from MarketBeat Media Is Abbott's January Pullback a Good Time to Buy? Reported by Thomas Hughes. First Published: 1/24/2026. 
Key Points - Abbott Laboratories’ January pullback looks driven more by sentiment than fundamentals, putting shares back near a prior accumulation zone.
- Quarterly results showed solid sales growth, improving margins, and faster adjusted earnings growth despite a revenue miss.
- A long dividend-growth track record and potential upside implied by analyst targets underpin the bullish rebound case.
Abbott Laboratories (NYSE: ABT)'s January 2026 pullback makes the stock look attractively valued. The move, driven more by market angst than by fundamental weakness, appears to be a knee-jerk overreaction that has pushed the shares back into the buy zone. 
Amazon has quietly poured $144 million into a secretive AI chip company, and committed to buying a staggering $650 million of their product. Why? Because this obscure startup holds the key to unleashing the full potential of Nvidia's revolutionary Blackwell chip. Discover the company at the heart of the AI arms race. This zone aligns with price action from 2022–2024, when Abbott was recovering from post-COVID revenue contraction and institutions were actively accumulating the stock. Abbott Laboratories Growth Accelerates At worst, Abbott's Q4 results and guidance missed some expectations. Even so, revenue of $11.46 billion was up 4.5% year-over-year, margins improved, and adjusted earnings accelerated. Revenue growth lagged consensus by several hundred basis points, but margin strength helped offset that; adjusted earnings per share (EPS) rose 12%, coming in slightly above consensus. By segment, the results highlighted the strength of Abbott's diversified healthcare portfolio. Nutrition and Diagnostics contracted — Nutrition declined nearly 9% — but that weakness was offset by solid gains in Established Pharmaceuticals and Med Tech. Established Pharmaceuticals grew about 9%, driven by generics and emerging markets, while Med Tech climbed roughly 12.3%, with strength across most subsegments. Margin performance was generally positive, helped by a favorable product mix, stronger Med Tech results, reduced COVID-19-related revenue and operational improvements, though margins were slightly below some analyst expectations. Looking ahead, management expects improvement to continue, forecasting roughly 10% earnings growth in 2026 — ahead of revenue — which should be enough to sustain the company's capital return program. Abbott's capital returns are central to the investment case. The company is a Dividend King, having raised its payout for more than 50 consecutive years, and it appears well positioned to continue that trend. After the pullback the stock yields about 2.5%, and the payout ratio is below 50% of consensus earnings, leaving ample cash flow for share buybacks, which help offset the impact of dilutive share-based compensation. Analysts See a Robust Rebound Possible Some analysts flagged the revenue miss, but no broad rating or price-target changes were announced the morning of the release. The prevailing view is that this is a fundamentally healthy company that can continue returning capital while investing in growth, and the long-term growth outlook remains meaningful. MarketBeat's consensus share price target suggests the stock could rebound as much as 30%, potentially setting new all-time highs, while even the low-end targets imply some upside. Key catalysts include expansion of the Med Tech portfolio, AI integration across operations and products, margin improvement and strategic acquisitions. The planned acquisition of Exact Sciences is one example cited for expanding Abbott's revenue and profit streams as well as its product pipeline. While the recent decline has been sharp and could deepen, institutions that accumulated shares through 2025 are likely to remain buyers at discounted prices. Early technical support appears in the $105–$110 range, though it's not yet confirmed. The risk is that ABT could fall to the lower end of a target buy zone before recovering, potentially reaching the mid-$90s or lower.
| 
